Myoglobin and left ventricular ejection fraction as predictive markers for death in children with fulminant

Tingting Xie1, Xiaodong Zang2, Yingying Xiong2

  • 1Department of Pediatrics, Provincial Hospital Affiliated to Anhui Medical University, Hefei, China.

Frontiers in Pediatrics
|October 3, 2022
PubMed

Insights

Myoglobin (MYO) and left ventricular ejection fraction (LVEF) levels predict outcomes in children with fulminant myocarditis (FM). Combining MYO and LVEF improves prognostic accuracy for this severe pediatric heart condition.

Area of Science:

  • Pediatric Cardiology
  • Critical Care Medicine
  • Biomarker Research

Background:

  • Fulminant myocarditis (FM) is a severe pediatric heart condition causing rapid cardiac dysfunction and high mortality.
  • Identifying prognostic factors is crucial for managing children with FM.

Purpose of the Study:

  • To investigate clinical characteristics and prognostic factors in children diagnosed with FM.
  • To determine predictors of in-hospital mortality in pediatric FM cases.

Main Methods:

  • A cohort of 37 pediatric patients with FM was analyzed retrospectively.
  • Multivariate logistic regression and ROC curve analysis identified predictors of mortality.
  • Patients were categorized into survival (25) and death (12) groups.

Main Results:

  • Children in the death group had higher levels of procalcitonin, creatine kinase, and myoglobin (MYO) compared to survivors.
  • Left ventricular ejection fraction (LVEF) was significantly lower in the death group.
  • MYO and LVEF were identified as independent predictors of mortality in pediatric FM, with combined detection showing higher predictive value.

Conclusions:

  • Myoglobin (MYO) and left ventricular ejection fraction (LVEF) serve as valuable prognostic markers for fulminant myocarditis in children.
  • The combined assessment of MYO and LVEF enhances the accuracy of disease severity evaluation and prognosis prediction.
  • These biomarkers hold significant clinical utility for managing pediatric FM patients.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
285
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
19
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
23
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
13
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
37
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
19